儿童造血干细胞移植存活者的慢性疾病负担与衰弱:圣犹达终身队列研究报告
本研究基于圣犹达终身队列,比较儿童血液恶性肿瘤经造血干细胞移植(HSCT,n=112)或常规治疗(n=1106)后慢性疾病与衰弱状况。HSCT存活者3-4级慢性疾病比例更高(81.3% vs 69.2%,P=.007),至25岁时3-4级事件发生率为148/100 vs 60/100(P<.001),第二肿瘤、3-4级心血管与肺部疾病及衰弱比例均更高。
要点
- HSCT存活者3-4级慢性疾病比例高于常规治疗者(81.3% vs 69.2%,P=.007)。
- 至25岁,HSCT存活者3-4级事件148/100,常规治疗者60/100(P<.001)。
- HSCT后第二肿瘤、3-4级心血管与肺部疾病及衰弱比例均更高。
核心结论
- 儿童血液恶性肿瘤HSCT存活者较常规治疗者具有更高的严重慢性疾病和衰弱负担,结果强调需要临床随访并为制定预防和/或干预策略提供数据。
研究设计与样本
- 圣犹达终身队列研究,纳入儿童血液恶性肿瘤后接受HSCT(n=112)或常规治疗(n=1106)的参与者。
- 慢性疾病和衰弱健康状态经临床评估,分别按修改版常见不良事件术语标准(版本4.03)和Fried衰弱标准分类。
- 112例移植中79例为异基因移植(41例同胞供者、34例无关供者、4例其他亲缘供者);25例异基因移植受者有慢性移植物抗宿主病史。
主要发现
- HSCT存活者中重度、致残或危及生命(3-4级)慢性疾病比例高于常规治疗者(81.3% vs 69.2%,P=.007)。
- 至25岁,HSCT存活者3-4级事件发生率为148/100,常规治疗存活者为60/100(P<.001)。
- HSCT后第二肿瘤比例高于常规治疗(17.0% vs 7.9%,P=.003)。
- HSCT后3-4级心血管疾病比例高于常规治疗(19.6% vs 10.2%,P=.004),3-4级肺部疾病比例亦更高(16.1% vs 4.6%,P<.001)。
- HSCT后衰弱健康比例高于常规治疗(7.1% vs 1.6%,P<.001)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Outcomes of hematopoietic stem cell transplantation (HSCT) have markedly improved over the past 2 decades, underscoring a need to better understand the long-term health effects of this intensive treatment modality. We describe the burden of chronic medical conditions and frail health among St. Jude Lifetime Cohort Study participants treated for childhood hematologic malignancies with HSCT (n = 112) or with conventional therapy (n = 1106). Chronic conditions and frail health were ascertained clinically and classified according to a modified version of the Common Terminology Criteria for Adverse Events (version 4.03) and the Fried Frailty Criteria. Seventy-nine transplants were allogeneic (41 from a sibling donor, 34 unrelated, and 4 others from related donor). Twenty-five allogeneic donor recipients had a history of chronic graft-versus-host disease. Compared to those treated with conventional therapy, a higher percentage of HSCT survivors had severe, disabling, or life threatening (grade 3-4) chronic conditions (81.3% vs 69.2%, P = .007). By age 25 years, HSCT survivors experienced 148 grade 3-4 events/100 compared to 60 among conventional therapy survivors (P < .001). Percentages of survivors with second neoplasms (17.0% vs 7.9%, P = .003), grade 3-4 cardiovascular (19.6% vs 10.2%, P = .004) and pulmonary (16.1% vs 4.6%, P < .001) conditions, and frail health (7.1% vs 1.6%, P < .001) were higher after HSCT than conventional therapy. These results underscore the need for clinical follow-up and provide data to guide the development of prevention and/or intervention strategies for this vulnerable population.
引用
- Eissa HM, Lu L, Baassiri M, et al. Chronic disease burden and frailty in survivors of childhood HSCT: a report from the St. Jude Lifetime Cohort Study. Blood Adv. 2017. PMID: 29296872. doi:10.1182/bloodadvances.2017010280
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。